Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
MSPR vs CLVT vs VRSK vs CLCO vs MSCI
Revenue, margins, valuation, and 5-year total return — side by side.
Information Technology Services
Consulting Services
Marine Shipping
Financial - Data & Stock Exchanges
MSPR vs CLVT vs VRSK vs CLCO vs MSCI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Information Technology Services | Consulting Services | Marine Shipping | Financial - Data & Stock Exchanges |
| Market Cap | $50M | $1.78B | $22.52B | $511M | $42.62B |
| Revenue (TTM) | $10M | $2.45B | $3.10B | $331M | $3.13B |
| Net Income (TTM) | $-719M | $-137M | $910M | $59M | $1.32B |
| Gross Margin | 26.3% | 66.5% | 67.4% | 61.8% | 82.4% |
| Operating Margin | -127.9% | 5.0% | 44.9% | 43.1% | 54.7% |
| Forward P/E | — | 3.7x | 22.5x | 12.1x | 29.8x |
| Total Debt | $795M | $4.48B | $5.04B | $1.31B | $6.31B |
| Cash & Equiv. | $12M | $329M | $2.18B | $165M | $515M |
MSPR vs CLVT vs VRSK vs CLCO vs MSCI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| MSP Recovery, Inc. (MSPR) | 100 | 0.3 | -99.7% |
| Clarivate Plc (CLVT) | 100 | 54.7 | -45.3% |
| Verisk Analytics, I… (VRSK) | 100 | 62.4 | -37.6% |
| Cool Company Ltd. (CLCO) | 100 | 121.4 | +21.4% |
| MSCI Inc. (MSCI) | 100 | 97.6 | -2.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MSPR vs CLVT vs VRSK vs CLCO vs MSCI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MSPR ranks third and is worth considering specifically for growth exposure.
- Rev growth 136.8%, EPS growth -127.8%, 3Y rev CAGR 7.7%
- 136.8% revenue growth vs CLCO's -10.8%
CLVT is the clearest fit if your priority is value.
- Lower P/E (3.7x vs 12.1x)
Among these 5 stocks, VRSK doesn't own a clear edge in any measured category.
CLCO carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.16, current ratio 0.73x
- Beta 0.16, yield 14.2%, current ratio 0.73x
- Beta 0.16 vs MSPR's 1.38
- 14.2% yield, vs MSCI's 1.2%, (2 stocks pay no dividend)
MSCI is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 11 yrs, beta 0.58, yield 1.2%
- 7.2% 10Y total return vs VRSK's 133.5%
- PEG 1.76 vs VRSK's 2.63
- 38.4% margin vs MSPR's -73.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 136.8% revenue growth vs CLCO's -10.8% | |
| Value | Lower P/E (3.7x vs 12.1x) | |
| Quality / Margins | 38.4% margin vs MSPR's -73.3% | |
| Stability / Safety | Beta 0.16 vs MSPR's 1.38 | |
| Dividends | 14.2% yield, vs MSCI's 1.2%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +57.7% vs MSPR's -99.7% | |
| Efficiency (ROA) | 24.0% ROA vs MSPR's -41.4%, ROIC 34.9% vs -69.7% |
MSPR vs CLVT vs VRSK vs CLCO vs MSCI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
MSPR vs CLVT vs VRSK vs CLCO vs MSCI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MSCI leads in 3 of 6 categories
CLVT leads 1 • MSPR leads 0 • VRSK leads 0 • CLCO leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
MSCI leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MSCI is the larger business by revenue, generating $3.1B annually — 319.4x MSPR's $10M. MSCI is the more profitable business, keeping 38.4% of every revenue dollar as net income compared to MSPR's -73.3%. On growth, CLCO holds the edge at +9.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $10M | $2.4B | $3.1B | $331M | $3.1B |
| EBITDAEarnings before interest/tax | -$659M | $878M | $1.7B | $222M | $2.0B |
| Net IncomeAfter-tax profit | -$719M | -$137M | $910M | $59M | $1.3B |
| Free Cash FlowCash after capex | -$11M | $597M | $1.1B | -$348M | $1.5B |
| Gross MarginGross profit ÷ Revenue | +26.3% | +66.5% | +67.4% | +61.8% | +82.4% |
| Operating MarginEBIT ÷ Revenue | -127.9% | +5.0% | +44.9% | +43.1% | +54.7% |
| Net MarginNet income ÷ Revenue | -73.3% | -5.6% | +29.3% | +17.8% | +38.4% |
| FCF MarginFCF ÷ Revenue | -107.9% | +24.4% | +36.3% | -105.0% | +49.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | -94.6% | -1.4% | +3.9% | +9.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -3.2% | +58.2% | +4.8% | -100.0% | +49.1% |
Valuation Metrics
CLVT leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 5.3x trailing earnings, CLCO trades at a 86% valuation discount to MSCI's 37.6x P/E. Adjusting for growth (PEG ratio), MSCI offers better value at 2.22x vs VRSK's 3.10x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $50M | $1.8B | $22.5B | $511M | $42.6B |
| Enterprise ValueMkt cap + debt − cash | $833M | $5.9B | $25.4B | $1.7B | $48.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -9.27x | 26.48x | 5.31x | 37.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 3.73x | 22.47x | 12.09x | 29.83x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 3.10x | — | 2.22x |
| EV / EBITDAEnterprise value multiple | — | 7.15x | 15.12x | 7.41x | 25.06x |
| Price / SalesMarket cap ÷ Revenue | 2.76x | 0.72x | 7.33x | 1.59x | 13.60x |
| Price / BookPrice ÷ Book value/share | — | 0.39x | 77.18x | 0.68x | — |
| Price / FCFMarket cap ÷ FCF | — | 4.86x | 18.89x | — | 27.51x |
Profitability & Efficiency
MSCI leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
VRSK delivers a 4.4% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-56 for MSPR. CLVT carries lower financial leverage with a 0.92x debt-to-equity ratio, signaling a more conservative balance sheet compared to VRSK's 16.26x. On the Piotroski fundamental quality scale (0–9), MSCI scores 8/9 vs MSPR's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -55.9% | -2.8% | +4.4% | +7.5% | — |
| ROA (TTM)Return on assets | -41.4% | -1.2% | +16.7% | +2.6% | +24.0% |
| ROICReturn on invested capital | -69.7% | +0.6% | +33.0% | +6.7% | +34.9% |
| ROCEReturn on capital employed | -67.7% | +0.7% | +39.6% | +8.7% | +44.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 5 | 5 | 8 |
| Debt / EquityFinancial leverage | — | 0.92x | 16.26x | 1.72x | — |
| Net DebtTotal debt minus cash | $782M | $4.2B | $2.9B | $1.1B | $5.8B |
| Cash & Equiv.Liquid assets | $12M | $329M | $2.2B | $165M | $515M |
| Total DebtShort + long-term debt | $795M | $4.5B | $5.0B | $1.3B | $6.3B |
| Interest CoverageEBIT ÷ Interest expense | -2.49x | 0.47x | 7.87x | 1.36x | 7.67x |
Total Returns (Dividends Reinvested)
MSCI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MSCI five years ago would be worth $12,876 today (with dividends reinvested), compared to $25 for MSPR. Over the past 12 months, CLCO leads with a +57.7% total return vs MSPR's -99.7%. The 3-year compound annual growth rate (CAGR) favors MSCI at 8.6% vs MSPR's -86.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -55.7% | -14.2% | -22.0% | +0.3% | +3.9% |
| 1-Year ReturnPast 12 months | -99.7% | -35.6% | -43.6% | +57.7% | +6.3% |
| 3-Year ReturnCumulative with dividends | -99.8% | -63.3% | -15.9% | +6.2% | +28.0% |
| 5-Year ReturnCumulative with dividends | -99.8% | -90.0% | -0.2% | +1.9% | +28.8% |
| 10-Year ReturnCumulative with dividends | -99.8% | -71.0% | +133.5% | +1.9% | +717.0% |
| CAGR (3Y)Annualised 3-year return | -86.5% | -28.4% | -5.6% | +2.0% | +8.6% |
Risk & Volatility
Evenly matched — VRSK and CLCO each lead in 1 of 2 comparable metrics.
Risk & Volatility
VRSK is the less volatile stock with a -0.08 beta — it tends to amplify market swings less than MSPR's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLCO currently trades 96.7% from its 52-week high vs MSPR's 0.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 1.18x | -0.08x | 0.16x | 0.58x |
| 52-Week HighHighest price in past year | $14.00 | $4.77 | $322.92 | $10.00 | $626.28 |
| 52-Week LowLowest price in past year | $0.03 | $1.66 | $161.70 | $5.78 | $501.08 |
| % of 52W HighCurrent price vs 52-week peak | +0.3% | +58.3% | +53.2% | +96.7% | +93.5% |
| RSI (14)Momentum oscillator 0–100 | 49.0 | 58.8 | 43.9 | 41.8 | 57.8 |
| Avg Volume (50D)Average daily shares traded | 45K | 5.5M | 1.9M | 104K | 519K |
Analyst Outlook
Evenly matched — CLCO and MSCI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CLVT as "Hold", VRSK as "Hold", CLCO as "Hold", MSCI as "Buy". Consensus price targets imply 34.5% upside for VRSK (target: $231) vs 15.2% for MSCI (target: $674). For income investors, CLCO offers the higher dividend yield at 14.24% vs VRSK's 1.05%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | — | $3.30 | $231.25 | — | $674.33 |
| # AnalystsCovering analysts | — | 20 | 25 | 1 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.1% | +14.2% | +1.2% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 7 | 0 | 11 |
| Dividend / ShareAnnual DPS | — | — | $1.81 | $1.38 | $7.20 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +12.6% | +2.8% | 0.0% | +5.8% |
MSCI leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CLVT leads in 1 (Valuation Metrics). 2 tied.
MSPR vs CLVT vs VRSK vs CLCO vs MSCI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MSPR or CLVT or VRSK or CLCO or MSCI a better buy right now?
For growth investors, MSP Recovery, Inc.
(MSPR) is the stronger pick with 136. 8% revenue growth year-over-year, versus -10. 8% for Cool Company Ltd. (CLCO). Cool Company Ltd. (CLCO) offers the better valuation at 5. 3x trailing P/E (12. 1x forward), making it the more compelling value choice. Analysts rate MSCI Inc. (MSCI) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MSPR or CLVT or VRSK or CLCO or MSCI?
On trailing P/E, Cool Company Ltd.
(CLCO) is the cheapest at 5. 3x versus MSCI Inc. at 37. 6x. On forward P/E, Clarivate Plc is actually cheaper at 3. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: MSCI Inc. wins at 1. 76x versus Verisk Analytics, Inc. 's 2. 63x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — MSPR or CLVT or VRSK or CLCO or MSCI?
Over the past 5 years, MSCI Inc.
(MSCI) delivered a total return of +28. 8%, compared to -99. 8% for MSP Recovery, Inc. (MSPR). Over 10 years, the gap is even starker: MSCI returned +717. 0% versus MSPR's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MSPR or CLVT or VRSK or CLCO or MSCI?
By beta (market sensitivity over 5 years), Verisk Analytics, Inc.
(VRSK) is the lower-risk stock at -0. 08β versus MSP Recovery, Inc. 's 1. 38β — meaning MSPR is approximately -1745% more volatile than VRSK relative to the S&P 500. On balance sheet safety, Clarivate Plc (CLVT) carries a lower debt/equity ratio of 92% versus 16% for Verisk Analytics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MSPR or CLVT or VRSK or CLCO or MSCI?
By revenue growth (latest reported year), MSP Recovery, Inc.
(MSPR) is pulling ahead at 136. 8% versus -10. 8% for Cool Company Ltd. (CLCO). On earnings-per-share growth, the picture is similar: Clarivate Plc grew EPS 68. 8% year-over-year, compared to -127. 8% for MSP Recovery, Inc.. Over a 3-year CAGR, CLCO leads at 25. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MSPR or CLVT or VRSK or CLCO or MSCI?
MSCI Inc.
(MSCI) is the more profitable company, earning 38. 4% net margin versus -1975. 4% for MSP Recovery, Inc. — meaning it keeps 38. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MSCI leads at 54. 7% versus -69. 8% for MSPR. At the gross margin level — before operating expenses — MSCI leads at 82. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MSPR or CLVT or VRSK or CLCO or MSCI more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, MSCI Inc. (MSCI) is the more undervalued stock at a PEG of 1. 76x versus Verisk Analytics, Inc. 's 2. 63x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Clarivate Plc (CLVT) trades at 3. 7x forward P/E versus 29. 8x for MSCI Inc. — 26. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRSK: 34. 5% to $231. 25.
08Which pays a better dividend — MSPR or CLVT or VRSK or CLCO or MSCI?
In this comparison, CLCO (14.
2% yield), MSCI (1. 2% yield), VRSK (1. 1% yield) pay a dividend. MSPR, CLVT do not pay a meaningful dividend and should not be held primarily for income.
09Is MSPR or CLVT or VRSK or CLCO or MSCI better for a retirement portfolio?
For long-horizon retirement investors, Verisk Analytics, Inc.
(VRSK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 08), 1. 1% yield, +133. 5% 10Y return). Both have compounded well over 10 years (VRSK: +133. 5%, MSPR: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MSPR and CLVT and VRSK and CLCO and MSCI?
These companies operate in different sectors (MSPR (Healthcare) and CLVT (Technology) and VRSK (Industrials) and CLCO (Industrials) and MSCI (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MSPR is a small-cap high-growth stock; CLVT is a small-cap quality compounder stock; VRSK is a mid-cap quality compounder stock; CLCO is a small-cap deep-value stock; MSCI is a mid-cap quality compounder stock. VRSK, CLCO, MSCI pay a dividend while MSPR, CLVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.